Maxim Group reaffirmed their buy rating on shares of Athersys Inc. (NASDAQ:ATHX) in a research note released on Wednesday morning. Maxim Group currently has a $10.00 price target on the biopharmaceutical company’s stock.
Several other analysts also recently commented on the stock. Zacks Investment Research raised shares of Athersys from a hold rating to a buy rating and set a $2.25 price objective for the company in a research report on Monday, August 15th. TheStreet raised shares of Athersys from a sell rating to a hold rating in a research report on Tuesday, May 31st.
Shares of Athersys (NASDAQ:ATHX) opened at 2.13 on Wednesday. Athersys has a 52-week low of $0.94 and a 52-week high of $2.90. The firm’s market capitalization is $181.01 million. The firm has a 50-day moving average of $1.97 and a 200 day moving average of $2.19.
Athersys (NASDAQ:ATHX) last announced its quarterly earnings data on Tuesday, August 9th. The biopharmaceutical company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.02. The company earned $0.60 million during the quarter, compared to the consensus estimate of $0.32 million. Athersys had a negative net margin of 18.89% and a negative return on equity of 25.42%. The company’s quarterly revenue was up 200.0% on a year-over-year basis. During the same quarter last year, the firm posted ($0.05) EPS. Analysts predict that Athersys will post ($0.20) EPS for the current year.
In related news, EVP John J. Harrington sold 15,000 shares of Athersys stock in a transaction on Friday, September 16th. The shares were sold at an average price of $1.96, for a total value of $29,400.00. Following the completion of the sale, the executive vice president now owns 619,639 shares of the company’s stock, valued at approximately $1,214,492.44. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 10.90% of the stock is currently owned by corporate insiders.
A number of hedge funds have recently bought and sold shares of the stock. BlackRock Fund Advisors increased its stake in Athersys by 822.9% in the second quarter. BlackRock Fund Advisors now owns 1,982,338 shares of the biopharmaceutical company’s stock valued at $4,302,000 after buying an additional 1,767,535 shares during the last quarter. BlackRock Investment Management LLC increased its stake in Athersys by 1,963.9% in the second quarter. BlackRock Investment Management LLC now owns 281,159 shares of the biopharmaceutical company’s stock valued at $610,000 after buying an additional 267,536 shares during the last quarter. Vanguard Group Inc. increased its stake in Athersys by 5.6% in the second quarter. Vanguard Group Inc. now owns 3,221,130 shares of the biopharmaceutical company’s stock valued at $6,990,000 after buying an additional 171,330 shares during the last quarter. Nationwide Fund Advisors acquired a new stake in Athersys during the second quarter valued at about $104,000. Finally, Alambic Investment Management L.P. increased its stake in Athersys by 164.3% in the second quarter. Alambic Investment Management L.P. now owns 56,300 shares of the biopharmaceutical company’s stock valued at $122,000 after buying an additional 35,000 shares during the last quarter. 17.76% of the stock is owned by institutional investors and hedge funds.
Athersys Company Profile
Athersys, Inc is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company’s MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients.
Receive News & Ratings for Athersys Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys Inc. and related companies with MarketBeat.com's FREE daily email newsletter.